Filtered By:
Drug: Metformin
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 446 results found since Jan 2013.
Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies
Prim Care Diabetes. 2021 Dec 22:S1751-9918(21)00211-4. doi: 10.1016/j.pcd.2021.11.006. Online ahead of print.ABSTRACTGlucagon-like peptide 1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i) are two novel classes of hypoglycemic agents. The relative cardiovascular effectiveness between these two drug classes in patients with type 2 diabetes (T2D) is unestablished due to the absence of large cardiovascular outcome trials directly comparing DPP-4i with GLP-1RA. We aimed to incorporate large propensity score-matched cohort studies to conduct a meta-analysis, to determine the relative effectiveness of ...
Source: Primary Care - December 26, 2021 Category: Primary Care Authors: Le Xu Xiao-Qin Zheng Xiao-Xian Liao Source Type: research
Effects of co-administration of metformin and evogliptin on cerebral infarct volume in the diabetic rat
Exp Neurol. 2021 Nov 12:113922. doi: 10.1016/j.expneurol.2021.113922. Online ahead of print.ABSTRACTPatients with diabetes suffer more severe ischemic stroke. A combination of metformin and dipeptidyl peptide-4 inhibitors is commonly prescribed to treat diabetes. Therefore, we aimed to determine if pretreatment with a combination of metformin and evogliptin, a dipeptidyl peptide-4 inhibitor, could reduce cerebral infarct volume in rats with streptozotocin-induced diabetes. After confirming diabetes induction, the rats were treated with vehicle, evogliptin, metformin, or evogliptin/metformin combination for 30 days. Then, s...
Source: Experimental Neurology - November 15, 2021 Category: Neurology Authors: Seong-Joon Lee Bok Seon Yoon Ji Man Hong Eun-Hye Joe Jin Soo Lee Source Type: research
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis
CONCLUSIONS: Findings from both standard and network meta-analyses of moderate- to high-certainty evidence suggest that GLP-1RA and SGLT2i are likely to reduce the risk of CVD mortality and all-cause mortality in people with established CVD; high-certainty evidence demonstrates that treatment with SGLT2i reduce the risk of hospitalisation for HF, while moderate-certainty evidence likely supports the use of GLP-1RA to reduce fatal and non-fatal stroke. Future studies conducted in the non-diabetic CVD population will reveal the mechanisms behind how these agents improve clinical outcomes irrespective of their glucose-lowerin...
Source: Cochrane Database of Systematic Reviews - October 25, 2021 Category: General Medicine Authors: Takayoshi Kanie Atsushi Mizuno Yoshimitsu Takaoka Takahiro Suzuki Daisuke Yoneoka Yuri Nishikawa Wilson Wai San Tam Jakub Morze Andrzej Rynkiewicz Yiqiao Xin Olivia Wu Rui Providencia Joey Sw Kwong Source Type: research
Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance
Conclusions
Metformin and sitagliptin were both effective in reducing fasting glucose and HbA1c levels in patients with recent TIA or minor ischaemic stroke and IGT. However, the reduction of glucose levels and sample size was relatively small. The clinical relevance, therefore, needs to be tempered. A phase III trial is needed to investigate whether medical treatment, compared with lifestyle intervention or a combination of both, not only improves glucose metabolism in IGT, but also leads to reduction of recurrent TIA or ischaemic stroke in these patients.
Trial registration number
NL3048.
Source: BMJ Open - September 16, 2021 Category: General Medicine Authors: Osei, E., Zandbergen, A., Brouwers, P. J. A. M., Mulder, L. J. M. M., Koudstaal, P., Lingsma, H., Dippel, D. W. J., den Hertog, H. Tags: Open access, Neurology Source Type: research
Neuroprotective effects of metformin on cerebral ischemia âreperfusion injury by regulating PI3K/Akt pathway
In conclusion, Met protected rats from cerebral I/R injury via reducing neuronal apoptosis and microglial inflammation through PI3K/Akt pathway.
Source: Brain and Behavior - September 2, 2021 Category: Neurology Authors: Cailian Ruan,
Hongtao Guo,
Jiaqi Gao,
Yiwei Wang,
Zhiyong Liu,
Jinyi Yan,
Xiaoji Li,
Haixia Lv Tags: ORIGINAL RESEARCH Source Type: research
Outcome and death risk of diabetes patients with Covid-19 receiving pre-hospital and in-hospital metformin therapies
COVID-19 has stroke Brazil harshly, deaths by COVID-19 in Brazil represent almost 13% of the total deaths by COVID-19 in the world, even though Brazilian population represents only 2.6% of the world population...
Source: Diabetology and Metabolic Syndrome - July 13, 2021 Category: Endocrinology Authors: Rodrigo Esaki Tamura, Said Muhammad Said, Leticia Mussin de Freitas and Ileana Gabriela Sanchez Rubio Tags: Research Source Type: research
Comparative assessment of in vitro BBB tight junction integrity following exposure to cigarette smoke and e-cigarette vapor: a quantitative evaluation of the protective effects of metformin using small-molecular-weight paracellular markers
ConclusionIn agreement with previous studies, our data showed the metformin could counteract the negative impact of TS and EC on BBB integrity, thus suggesting the possibility of repurposing this drug to afford cerebrovascular protection.
Source: Fluids and Barriers of the CNS - June 22, 2021 Category: Neuroscience Source Type: research
Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis
Conclusions/interpretationGenetically high plasma glucose has a causal impact on increased risk of ischaemic stroke. Treatment with glucose-lowering glucagon-like peptide-1 receptor agonists and thiazolidinediones reduces this risk. These results may guide clinicians in the treatment of individuals at high risk of ischaemic stroke.Graphical abstract
Source: Diabetologia - June 8, 2021 Category: Endocrinology Source Type: research
Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
Bioinformation. 2021 Mar 31;17(3):413-423. doi: 10.6026/97320630017413. eCollection 2021.ABSTRACTIt is of interest to evaluate the clinical effectiveness and safety of vildagliptin as monotherapy and combination therapy of vildagliptin and metformin for the management of type 2 diabetes mellitus (T2DM) patients in Indian settings. The study included patients with T2DM (aged >18 years) receiving vildagliptin monotherapy and vildagliptin in combination with metformin therapy of various strengths. Data related to demographics, risk factors, medical history, glycated hemoglobin (HbA1c) levels, and medical therapies were ret...
Source: Bioinformation - June 7, 2021 Category: Bioinformatics Authors: Sambit Das A K Gupta Biplab Bandyopadhyaya B Harish Darla Vivek Arya Mahesh Abhyankar Santosh Revankar Source Type: research
